Analysis reveals malignant cells in BPDCN show transcriptional heterogeneity, indicating PLD4's potential as a therapeutic target.
This study suggested a potential clonal origin of tumor cells, and revealed the transcriptional heterogeneity among malignant cells across different tissues in BPDCN. PLD4 was identified as a specific marker of malignant cells, aiding in the diagnosis of BPDCN and showing potential as a therapeutic target.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: